BRVE Braveheart Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2131524 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets3.3%
Debt / equity0.00x
Current ratio21.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | — | — |
| R&D expense | $17.54M | $11.12M | — | $9,000 | $0 | — |
| SG&A expense | $12.61M | $4.76M | — | $508,000 | $27,000 | — |
| Operating income | -$30.15M | -$15.88M | — | -$59.29M | -$381,000 | — |
| Net income | -$26.50M | -$14.99M | -$14.28M | -$59.12M | -$381,000 | -$99,000 |
| EBITDA | -$30.15M | — | — | -$59.29M | — | — |
| EPS (basic) | -0.51 | -2.51 | — | -10.05 | -0.14 | — |
| EPS (diluted) | -0.51 | -2.51 | — | -10.05 | -0.14 | — |
| Weighted avg. shares (diluted) | 52.10M | 7.40M | — | 5.88M | 2.79M | — |
| Balance sheet | ||||||
| Cash & equivalents | $121.29M | $122.83M | — | $67.53M | $2,000 | — |
| Current assets | $359.57M | $123.44M | — | — | — | — |
| PP&E, net | $20,000 | $23,000 | — | — | — | — |
| Total assets | $514.45M | $126.96M | — | — | — | — |
| Current liabilities | $16.67M | $9.06M | — | — | — | — |
| Total liabilities | $16.85M | $9.34M | — | — | — | — |
| Shareholders' equity | $497.60M | -$95.91M | -$78.39M | -$59.59M | -$477,000 | -$99,000 |
| Shares outstanding | 82.07M | 7.54M | — | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$24.37M | — | — | -$740,000 | — | — |
| Capital expenditure | $0 | — | — | $0 | — | — |
| Free cash flow | -$24.37M | — | — | -$740,000 | — | — |
| Investing cash flow | -$382.45M | — | — | -$32.73M | — | — |
| Financing cash flow | $405.28M | — | — | $101.00M | — | — |
| Depreciation & amortization | $3,000 | — | — | $0 | — | — |
| Stock-based compensation | $2.79M | — | — | $0 | — | — |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.